Quiet Comfort: New Details on COMP360 Psilocybin Administration Sessions for the Treatment of PTSD

Compass Pathways has announced the publication of a post-hoc analysis of support methods used in an open-label phase 2 study of investigational COMP360 synthetic psilocybin treatment in patients with posttraumatic stress disorder (PTSD). Documented speech production between participants and support providers during treatment administration sessions showed minimal interaction. Monitoring and support were linked by patients to presence, availability, reassurance, and validation.¹

The limited, nondirective nature of these interactions distinguishes this form of support from therapeutic dialogues typically used in conventional psychotherapy or other trauma-focused psychological treatments. Investigators found that the vast majority (78%) of the administration session was spent in silence. Support was minimal, yet relevant to patients’ feelings of safety and stability. Several participants described the support providers as a reliable and available resource if needed, but largely out of their awareness during treatment. Furthermore, nondirective support strategies promoted autonomy through the introspective psychedelic state. Participants felt empowered to sustain inward focus and self-navigate the treatment without the support provider leading, redirecting, or reinterpreting the experience in any way. The primary modes of support included reassurance and validation from physical proximity.

"When we examined what happens during a COMP360 session, patients spent the vast majority of the time, 78%, in silence, navigating the experience themselves. They valued our trained providers for a reassuring presence, but those providers were there to safeguard patients, not to lead, redirect, or reinterpret the experience, and it remained largely self-directed,” Guy Goodwin, MD, the chief medical officer of Compass Pathways, exclusively told Psychiatric Times. “The meaningful change comes from the psilocybin treatment itself. That sets it apart from how depression is typically treated: it is neither a daily antidepressant taken indefinitely, nor a medicine paired with a course of talk-based treatment. It is a distinct treatment paradigm, built around the medicine, with a standardized, nondirective model of support designed to keep patients safe.”

These findings were published in the Journal of Psychopharmacology.²

Compass has developed a systematic training and mentoring program to ensure and measure quality and consistent monitoring and support for participants across all COMP360 trials in treatment-resistant depression (TRD) and PTSD. Support providers for trials are trained using a manualized approach based on historical clinical experience and regulatory guidance, reinforced with ongoing mentorship. Support strategies include breath and body awareness, short verbal cues, and physical proximity.

“The monitoring and support we’ve incorporated across our COMP360 trials in both treatment-resistant depression and PTSD is designed to safeguard patients and protect data integrity during psychedelic treatment. Patients themselves have indicated they value a reassuring presence, but the key aspects of the experience are self-directed,” said Goodwin. “These findings reinforce that the rapid and durable symptom improvement observed in the open-label phase 2 PTSD trial was attributable to the psilocybin drug experience. It is incorrect to describe the treatment we are developing as psilocybin-assisted psychotherapy. We are happy to see these results published in the Journal of Psychopharmacology and excited to continue building upon the existing body of evidence supporting the transformative potential of COMP360 for the treatment of TRD and PTSD.”

References

1. Compass Pathways announces publication of post-hoc analysis demonstrating distinction of COMP360 trial monitoring & support from psychotherapy. News release. July 16, 2026. Accessed July 27, 2026. https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Publication-of-Post-Hoc-Analysis-Demonstrating-Distinction-of-COMP360-Trial-Monitoring--Support-from-Psychotherapy/default.aspx

2. Dougherty RF, Modlin NL, McGowan NM, et al. Silence is golden: documenting the speech production of participants and support providers in psilocybin administration sessions for the treatment of post-traumatic stress disorder. J Psychopharmacol. 2026:2698811261464988.